PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10428299-0 1999 NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells. pitavastatin 0-6 apolipoprotein B Homo sapiens 86-106 10428299-2 1999 The effect of compound NK-104 was studied, a new competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA-reductase), on apo B-100 synthesis and secretion from the human hepatoma cell line Hep G2. pitavastatin 23-29 apolipoprotein B Homo sapiens 146-155 10428299-9 1999 It is speculated that the ability of compound NK-104 to decrease apo B-100 secretion from Hep G2 cells is due to a decreased intracellular cholesterol availability. pitavastatin 46-52 apolipoprotein B Homo sapiens 65-74 26754586-0 2016 Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2 in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome. pitavastatin 10-22 apolipoprotein B Homo sapiens 36-43 33123903-6 2020 The results showed that pitavastatin treatment indeed not only decreased LDL-C, total cholesterol (TC), triglycerides (TG) and apolipoprotein B (ApoB) levels, and increased HDL cholesterol (HDL-C), but also reduced the cholesterol concentration of all of the LDL subfractions and the percentage of intermediate and small LDL subfractions. pitavastatin 24-36 apolipoprotein B Homo sapiens 127-143 33123903-6 2020 The results showed that pitavastatin treatment indeed not only decreased LDL-C, total cholesterol (TC), triglycerides (TG) and apolipoprotein B (ApoB) levels, and increased HDL cholesterol (HDL-C), but also reduced the cholesterol concentration of all of the LDL subfractions and the percentage of intermediate and small LDL subfractions. pitavastatin 24-36 apolipoprotein B Homo sapiens 145-149 26754586-3 2016 The aim of this study was to explore the effect of pitavastatin treatment and life style modification (LSM) on ApoB-48 and Lp-PLA2 levels in metabolic syndrome (MS) patients at relatively low risk for CVD, as a sub-analysis of a previous multi-center prospective study. pitavastatin 51-63 apolipoprotein B Homo sapiens 111-118 26754586-6 2016 RESULTS: Total cholesterol, low density lipoprotein cholesterol, non-high density lipoprotein cholesterol, and ApoB-100/A1 ratio were significantly improved in the pitavastatin+LSM group compared to the LSM only group (P<=0.001). pitavastatin 164-176 apolipoprotein B Homo sapiens 111-119 26754586-7 2016 Pitavastatin+LSM did not change the level of ApoB-48 in subjects overall, but the level of ApoB-48 was significantly lower in the higher mean baseline value group of ApoB-48. pitavastatin 0-12 apolipoprotein B Homo sapiens 91-98 26754586-7 2016 Pitavastatin+LSM did not change the level of ApoB-48 in subjects overall, but the level of ApoB-48 was significantly lower in the higher mean baseline value group of ApoB-48. pitavastatin 0-12 apolipoprotein B Homo sapiens 91-98 26754586-9 2016 CONCLUSION: Pitavastatin treatment and LSM significantly improved lipid profiles, ApoB-100/A1 ratio, and reduced ApoB-48 levels in the higher mean baseline value group of ApoB-48, but did not significantly alter the Lp-PLA2 levels. pitavastatin 12-24 apolipoprotein B Homo sapiens 82-90 26754586-9 2016 CONCLUSION: Pitavastatin treatment and LSM significantly improved lipid profiles, ApoB-100/A1 ratio, and reduced ApoB-48 levels in the higher mean baseline value group of ApoB-48, but did not significantly alter the Lp-PLA2 levels. pitavastatin 12-24 apolipoprotein B Homo sapiens 113-120 26754586-9 2016 CONCLUSION: Pitavastatin treatment and LSM significantly improved lipid profiles, ApoB-100/A1 ratio, and reduced ApoB-48 levels in the higher mean baseline value group of ApoB-48, but did not significantly alter the Lp-PLA2 levels. pitavastatin 12-24 apolipoprotein B Homo sapiens 171-178 23174369-3 2013 Between-group analysis did not reveal any differences except in the ratio of malondialdehyde (MDA)-LDL over apolipoprotein B-100 (MDA-LDL/apoB) in pitavastatin vs. atorvastatin group (-13% vs. -0.7%, p = 0.04). pitavastatin 147-159 apolipoprotein B Homo sapiens 108-128 23174369-3 2013 Between-group analysis did not reveal any differences except in the ratio of malondialdehyde (MDA)-LDL over apolipoprotein B-100 (MDA-LDL/apoB) in pitavastatin vs. atorvastatin group (-13% vs. -0.7%, p = 0.04). pitavastatin 147-159 apolipoprotein B Homo sapiens 138-142 23819752-6 2013 Compared with other statins, pitavastatin has distinct pharmacological features that translate into a broad range of actions on both apolipoprotein-B-containing and apolipoprotein-A-containing lipoproteins. pitavastatin 29-41 apolipoprotein B Homo sapiens 133-149 22472908-1 2012 Pitavastatin is a novel statin recently approved in the United States as an adjunctive therapy with diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, and triglycerides and to increase high-density lipoprotein cholesterol. pitavastatin 0-12 apolipoprotein B Homo sapiens 180-196 22679249-5 2013 Compared with pravastatin, pitavastatin provided greater decreases in total cholesterol and apolipoprotein B in all dose groups (p < 0.001) and triglycerides in the low-dose (p = 0.001) and higher-dose (p = 0.016) groups, and greater increases in high-density lipoprotein cholesterol in the intermediate-dose (p = 0.013) and higher-dose (p = 0.023) groups. pitavastatin 27-39 apolipoprotein B Homo sapiens 92-108 22152282-4 2011 Pitavastatin is a new member of the statin class whose distinct pharmacological features translate into a broad spectrum of action on both apoB-containing and apoA1-containing lipoprotein components of the atherogenic lipid profile. pitavastatin 0-12 apolipoprotein B Homo sapiens 139-143 21446776-2 2011 Pitavastatin is the newest member of the HMG-CoA reductase inhibitor family and is approved as adjunctive therapy to diet to reduce elevated levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, apolipoprotein (Apo) B, and triglycerides and to increase levels of high-density lipoprotein (HDL) cholesterol in adult patients with primary hyperlipidemia or mixed dyslipidemia. pitavastatin 0-12 apolipoprotein B Homo sapiens 213-235